ATE528989T1 - Kristalline feste rasagilin-base - Google Patents

Kristalline feste rasagilin-base

Info

Publication number
ATE528989T1
ATE528989T1 AT07862906T AT07862906T ATE528989T1 AT E528989 T1 ATE528989 T1 AT E528989T1 AT 07862906 T AT07862906 T AT 07862906T AT 07862906 T AT07862906 T AT 07862906T AT E528989 T1 ATE528989 T1 AT E528989T1
Authority
AT
Austria
Prior art keywords
rasagilin
base
crystalline solid
aminoindan
propargyl
Prior art date
Application number
AT07862906T
Other languages
English (en)
Inventor
Anton Frenkel
Tamas Koltai
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39536623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE528989(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE528989T1 publication Critical patent/ATE528989T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT07862906T 2006-12-14 2007-12-13 Kristalline feste rasagilin-base ATE528989T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87501106P 2006-12-14 2006-12-14
PCT/US2007/025583 WO2008076348A1 (en) 2006-12-14 2007-12-13 Crystalline solid rasagiline base

Publications (1)

Publication Number Publication Date
ATE528989T1 true ATE528989T1 (de) 2011-11-15

Family

ID=39536623

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07862906T ATE528989T1 (de) 2006-12-14 2007-12-13 Kristalline feste rasagilin-base

Country Status (24)

Country Link
US (4) US7750051B2 (de)
EP (1) EP2101569B1 (de)
JP (1) JP5623081B2 (de)
KR (1) KR101459744B1 (de)
CN (1) CN101557706B (de)
AT (1) ATE528989T1 (de)
AU (1) AU2007334428B2 (de)
CA (1) CA2672414A1 (de)
CY (1) CY1112511T1 (de)
DK (1) DK2101569T3 (de)
EA (1) EA016820B1 (de)
ES (1) ES2375761T3 (de)
HR (1) HRP20110980T1 (de)
IL (1) IL198985A0 (de)
MX (1) MX2009006251A (de)
NO (1) NO20092611L (de)
NZ (1) NZ577460A (de)
PL (1) PL2101569T3 (de)
PT (1) PT2101569E (de)
RS (1) RS52183B (de)
SI (1) SI2101569T1 (de)
UA (1) UA97502C2 (de)
WO (1) WO2008076348A1 (de)
ZA (1) ZA200903903B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
HRP20130622T1 (en) * 2005-02-17 2013-08-31 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
WO2006091657A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
JP2009521402A (ja) * 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
CA2643235C (en) * 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
AU2007334428B2 (en) 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CA2711817A1 (en) * 2008-01-11 2009-07-16 Teva Pharmaceutical Industries Ltd. Rasagiline formulations, their preparation and use
CA2723869C (en) 2008-06-02 2013-07-16 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
CA2727019A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
WO2009151625A1 (en) 2008-06-13 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline for parkinson's disease modification
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
EA021472B1 (ru) * 2008-06-19 2015-06-30 Тева Фармасьютикал Индастриз, Лтд. Способ получения и сушки твердого разагилина в форме основания
CN101606923B (zh) * 2008-06-20 2013-01-09 重庆医药工业研究院有限责任公司 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法
ITMI20081406A1 (it) * 2008-07-29 2010-01-30 Dipharma Francis Srl Forma cristallina di rasagilina e procedimento per la sua preparazione
EP2358658A4 (de) * 2008-11-20 2012-11-14 Reddys Lab Ltd Dr Herstellung von rasagilin und salzen davon
EP2218444A3 (de) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Rasagilinformulierung mit verzögerter Freisetzung
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
EP2298277A1 (de) * 2009-09-09 2011-03-23 Labtec GmbH Transdermale Pflasterformulierung
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2325159A1 (de) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Neuartige Salze von Rasagilin
MX2012007375A (es) 2009-12-22 2012-07-30 Teva Pharma 3-ceto-n-propargil 1-aminoindano.
WO2011121607A2 (en) 2010-03-29 2011-10-06 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
AU2011248904B2 (en) 2010-04-30 2014-02-27 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
WO2012015946A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
KR101853082B1 (ko) 2011-03-24 2018-04-27 테이코쿠 팔마 유에스에이, 인코포레이티드 활성제층 및 활성제 변환층을 포함하는 경피 조성물
EP2705021A2 (de) 2011-05-04 2014-03-12 Cadila Healthcare Limited Rasagilin und pharmazeutisch zulässige salze davon
AU2012323349A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-formyl-propargyl-aminoindan
EA201490760A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. R(+)-n-метилпропаргиламиноиндан
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
EP2610239A1 (de) 2012-01-02 2013-07-03 Dr. Reddy's Laboratories Ltd. Herstellung von Rasagilin-Hemitartrat
EP2827848B1 (de) 2012-03-21 2016-04-27 Synthon BV Stabilizierte pharmazeutische zubereitungen enthaltend salze von rasigiline
MX2015002062A (es) 2012-08-17 2015-06-05 Teva Pharma Formulaciones parenterales de rasagilina.
CN104797245B (zh) 2012-11-02 2018-05-04 帝国制药美国公司 丙炔基氨基茚满透皮组合物

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
US4529811A (en) 1981-03-02 1985-07-16 G. D. Searle & Co. Process for isolating organic compounds and lithium salt complexes useful in said process
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CN1031995C (zh) * 1991-01-02 1996-06-12 奥韦特有限公司 N-炔丙基-1-氨基茚满的r-对映体的制法
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5877218A (en) * 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
RU2161601C2 (ru) 1995-02-01 2001-01-10 Фармация Энд Апджон Компани 2-аминоинданы в качестве селективных лигандов допамина д3
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en) 1996-06-28 1997-09-02 Jame Fine Chemicals, Inc. Process for preparing antihistamine tannates
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DK0966435T3 (da) 1996-12-18 2005-08-15 Teva Pharma Aminoindanderivater
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
EP1052983A2 (de) 1998-01-27 2000-11-22 Thomas N. Thomas Verwendung eines mao-a oder mao-b inhibitors zur behandlung der gefässerkrankungen
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
IL141690A (en) 2001-02-27 2004-06-20 Isp Finetech Ltd Process for preparation of rasagiline and its salts
US6543155B2 (en) 2001-03-01 2003-04-08 National Agricultural Research Organization Freeze-dried product and process and apparatus for producing it
WO2003039525A1 (en) * 2001-11-05 2003-05-15 Krele Pharmaceuticals Llc Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
UA78854C2 (en) 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
ES2432117T3 (es) 2002-11-15 2013-11-29 Teva Pharmaceutical Industries Limited Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
JP5460947B2 (ja) 2003-09-03 2014-04-02 グラクソ グループ リミテッド 新規調製方法、塩、組成物及び使用
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
WO2006014973A2 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
WO2006057912A2 (en) 2004-11-24 2006-06-01 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
WO2006091657A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
JP2009521402A (ja) 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
CA2643235C (en) 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
US7573834B2 (en) * 2006-05-31 2009-08-11 Alcatel Lucent Method and system for allocating a group bit rate among multiple bonded pairs in a communications network
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
DK2101570T3 (da) 2006-12-14 2013-05-27 Teva Pharma Tannatsalt af rasagilin
AU2007334428B2 (en) 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CA2711817A1 (en) 2008-01-11 2009-07-16 Teva Pharmaceutical Industries Ltd. Rasagiline formulations, their preparation and use
WO2009122301A2 (en) 2008-03-31 2009-10-08 Actavis Group Ptc Ehf Rasagiline mesylate particles and process for the preparation thereof
CA2727019A1 (en) 2008-06-10 2009-12-17 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
US8334409B2 (en) 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
EA021472B1 (ru) * 2008-06-19 2015-06-30 Тева Фармасьютикал Индастриз, Лтд. Способ получения и сушки твердого разагилина в форме основания
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
CA2777185A1 (en) * 2009-10-09 2011-04-14 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of progressive supranuclear palsy
MX2012007375A (es) * 2009-12-22 2012-07-30 Teva Pharma 3-ceto-n-propargil 1-aminoindano.
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
WO2012015946A1 (en) * 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
KR20140023872A (ko) * 2010-10-26 2014-02-27 테바 파마슈티컬 인더스트리즈 리미티드 중수소 농축 라사길린
EA201490760A1 (ru) * 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. R(+)-n-метилпропаргиламиноиндан
AU2012323349A1 (en) * 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-formyl-propargyl-aminoindan
EP2766007A4 (de) * 2011-10-10 2015-03-25 Teva Pharma Rasagilin-citramid

Also Published As

Publication number Publication date
IL198985A0 (en) 2010-02-17
CA2672414A1 (en) 2008-06-26
PT2101569E (pt) 2012-01-13
EP2101569A1 (de) 2009-09-23
EA200970581A1 (ru) 2009-12-30
JP2010513282A (ja) 2010-04-30
US20150038744A1 (en) 2015-02-05
US20100145101A1 (en) 2010-06-10
CN101557706B (zh) 2013-08-07
HK1129276A1 (en) 2009-11-27
CN101557706A (zh) 2009-10-14
US8614252B2 (en) 2013-12-24
RS52183B (sr) 2012-10-31
JP5623081B2 (ja) 2014-11-12
AU2007334428A1 (en) 2008-06-26
US7750051B2 (en) 2010-07-06
MX2009006251A (es) 2009-10-12
DK2101569T3 (da) 2012-01-30
AU2007334428B2 (en) 2014-05-29
HRP20110980T1 (hr) 2012-02-29
PL2101569T3 (pl) 2012-03-30
WO2008076348A1 (en) 2008-06-26
KR20090089894A (ko) 2009-08-24
US20080161408A1 (en) 2008-07-03
NZ577460A (en) 2012-01-12
NO20092611L (no) 2009-09-11
WO2008076348A8 (en) 2008-08-21
KR101459744B1 (ko) 2014-11-20
ES2375761T3 (es) 2012-03-06
EP2101569A4 (de) 2009-12-02
US20100144887A1 (en) 2010-06-10
SI2101569T1 (sl) 2012-02-29
EP2101569B1 (de) 2011-10-19
CY1112511T1 (el) 2015-12-09
UA97502C2 (ru) 2012-02-27
ZA200903903B (en) 2010-08-25
EA016820B1 (ru) 2012-07-30

Similar Documents

Publication Publication Date Title
ATE528989T1 (de) Kristalline feste rasagilin-base
JO2778B1 (en) Certain Compounds, Compositions and Methods
TW200732349A (en) Anti-OX40L antibodies and methods using same
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
MY153915A (en) Organic compounds
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
NO20073725L (no) CCI-779-polymorf og dens anvendelse
DK1808165T3 (da) Törre formuleringer af aripiprazol
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
TW200738649A (en) Calcilytic compounds
ATE552832T1 (de) Antidepressivum-propharmaka
ATE444990T1 (de) Spritzbare akustikmassen
ATE539082T1 (de) Oxazinylisoflavonoidverbindungen, medikamente und anwendungen
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
BRPI0417205A (pt) composições farmacêuticas
NO20091386L (no) Fenyloksyanilinderivater

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2101569

Country of ref document: EP